{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate", "query": { "intervention": "Abiraterone acetate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 203, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T14:39:45.856Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04493853", "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Abiraterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1012, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 33, "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493853" }, { "nct_id": "NCT02353715", "title": "Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Sipuleucel-T", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 38, "start_date": "2015-07-07", "completion_date": "2018-11-14", "has_results": false, "last_update_posted_date": "2020-12-24", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02353715" }, { "nct_id": "NCT04691804", "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "Fuzuloparib , Abiraterone acetate and Prednisone", "type": "DRUG" }, { "name": "Fuzuloparib Placebo， Abiraterone acetate and Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu HengRui Medicine Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 496, "start_date": "2021-03-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 17, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04691804" }, { "nct_id": "NCT02903368", "title": "Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 118, "start_date": "2016-10-19", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 4, "location_summary": "La Jolla, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903368" }, { "nct_id": "NCT04734730", "title": "Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Sensitive Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 70, "start_date": "2021-05-04", "completion_date": "2027-08-23", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04734730" }, { "nct_id": "NCT06329830", "title": "177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer", "Castration-resistant Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "Niraparib abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2024-10", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06329830" }, { "nct_id": "NCT01786265", "title": "Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Nilutamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 310, "start_date": "2013-02-05", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786265" }, { "nct_id": "NCT05520138", "title": "Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 5506, "start_date": "2022-08-29", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05520138" }, { "nct_id": "NCT02913196", "title": "Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2016-12-30", "completion_date": "2025-10-15", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 2, "location_summary": "Omaha, Nebraska • New York, New York", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02913196" }, { "nct_id": "NCT06650579", "title": "REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Prostate Carcinoma", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography Angiography", "type": "PROCEDURE" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 72, "start_date": "2025-01-31", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-07T14:39:45.856Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06650579" } ] }